Novel use of rituximab in macrophage activation syndrome secondary to systemic lupus erythematosus

Macrophage activation syndrome (MAS) is a rare disease characterised by aberrant immune hyperactivation of T lymphocytes and macrophages driven by cytokine dysfunction. The HLH-2004 protocol is commonly used for the treatment of MAS, but significant toxicities are associated. We describe a case of M...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:BMJ Case Rep
Main Authors: Junga, Zachary, Stitt, Rodger, Tracy, Christopher, Keith, Michael
פורמט: Artigo
שפה:Inglês
יצא לאור: BMJ Publishing Group 2017
נושאים:
Novel Treatment (New Drug/Intervention; Established Drug/Procedure in New Situation)
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC5624074/
https://ncbi.nlm.nih.gov/pubmed/28827301
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bcr-2017-221347
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים